InvestorsHub Logo
Followers 197
Posts 24669
Boards Moderated 0
Alias Born 04/03/2010

Re: ATLnsider post# 692795

Tuesday, 05/21/2024 11:24:14 AM

Tuesday, May 21, 2024 11:24:14 AM

Post# of 700013
I agree with your description that the two drugs are coadministered. I do not think that means that it is a “maturation agent” in this context. I think that is back to the notion that it’s one drug. I do agree that it makes sense for the company to find a way, as soon as possible, to work with Oncovir to ensure that patients, going forward, not just in trials, can access and have Poly-ICLC, specifically Hiltonol, with their DCVax-L injections, as an adjuvant treatment that stimulates the immune system broadly, not just the dendritic cells in the vaccine. It does so by pretending to be viral DNA. It would be good if the companies find ways to collaborate, work together and commercialize in a manner that provides patients with the best possible solution, as well as positions both companies to prosper from the collaboration.
Bullish
Bullish

I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News